Efficacy and Safety of Alirocumab as Add‐on Therapy in High–Cardiovascular‐Risk Patients With Hypercholesterolemia Not Adequately Controlled With Atorvastatin (20 or 40 mg) or Rosuvastatin (10 or 20 mg): Design and Rationale of the ODYSSEY OPTIONS Studies

The phase 3 ODYSSEY OPTIONS studies (OPTIONS I, NCT01730040; OPTIONS II, NCT01730053) are multicenter, multinational, randomized, double‐blind, active‐comparator, 24‐week studies evaluating the efficacy and safety of alirocumab, a fully human monoclonal antibody targeting proprotein convertase subti...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cardiol
Main Authors: Robinson, Jennifer G., Colhoun, Helen M., Bays, Harold E., Jones, Peter H., Du, Yunling, Hanotin, Corinne, Donahue, Stephen
Formato: Artigo
Idioma:Inglês
Publicado em: Wiley Periodicals, Inc. 2014
Assuntos:
Trial Designs
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4282386/
https://ncbi.nlm.nih.gov/pubmed/25269777
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/clc.22327
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados